Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy
An Open-Label, Dose-Escalating Efficacy and Safety Study of Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy
Sponsor: Medical Research Laboratories International
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Medical Research Laboratories International
- Familial Hypercholesterolemia · Phase PHASE2 · Apr 2005
- Familial Hypercholesterolemia · Phase PHASE2 · Apr 2005
More terminations from Medical Research Laboratories International
Listed as NCT00080132, this PHASE2 trial focuses on Hypertriglyceridemia and remains terminated or withdrawn. Sponsored by Medical Research Laboratories International, it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Oct 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical Research Laboratories International
For direct contact, visit the study record on ClinicalTrials.gov .